Direct Flow Medical said it raised nearly $31 million in a Series C funding round it hopes will eventually gross nearly $60 million.
The company is developing transcatheter replacements for the aortic and mitral heart valves. Direct Flow’s transcatheter aortic valve implant won CE Mark approval in the European Union in January 2013; enrollment is under way in a 1,000-patient U.S. pivotal trial of the device.
In February, the company debuted its TMVR entry, saying it hopes to begin 1st-in-human studies by the end of this year.
